Company Overview



Company Overview

Eli Lilly and Company

Company Overview代写 Eli Lilly and Company is a multinational pharmaceutical corporation. It is located in Indianapolis in Indiana.


Company Description  Company Overview代写

Eli Lilly and Company is a multinational pharmaceutical corporation. It is located in Indianapolis in Indiana. It was established in 1876 and operate in more than 125 countries globally (Lilly Home, n.d). It operates in the pharmaceutical industry developing, manufacturing, distributing and marketing pharmaceutical products for humans and animals. Among other companies that Eli Lilly and Company compete with include Pfizer, Merck, gsk and Amgen, Vivus, MannKind Corporation and more.

Accounting Standard  Company Overview代写

The company uses Generally Accepted Accounting Principles in its financial reporting. The use of GAAP standards is for understandability of its financial statements and reports by the international stakeholders. The report states its application of GAAP as the primary reporting standard (Eli Lilly and Company, 2018). The company applied GAAP as it focuses on the conventional methodology of using literature to explain the various accounting interpretations and achievements. The accounting statement includes only those disclosures allowed by the GAAPs like deduction of expenses and depreciation to get net profit.

The standard also allows the company to make estimations and assumptions that may affect the reported assets and liabilities, as well as other disclosures. Contrary to the International Financial Reporting Standard, GAAP is ruled based by which the disclosure follows a specific structure and items for inclusion in financial statement and balance sheet.

Press Release Summary  Company Overview代写

Strategic plan

In the year ended 2018, the company had numerous press releases all focusing on various announcements from new products, acquisitions, investments made, dividend payments, and other programs in the pipeline in the company’s strategic plan (Lilly Media, 2018). The press release for the year ended 2018 focused on guidance and reviews of financial performance, and overview of investment opportunities. The statement was given at the investment community meeting in Indianapolis.

The statement discusses the expected revenue in 2019 which was projected to be $25.3 billion and $25.8 billion. The predicted opportunities were to be driven by sales volume from the new medicines including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant, and Lartruvo as well as Emgality. The earning per share was projected to range between $5.52 to $5.62 or $5.90 to $6.00 on a reported basis and non-GAAP basis respectively.

Also, the launch of over ten new products over the past five years, it was an indication of future growth in 2019. As such, it was expected to achieve six percent compound revenue by 2020 with much growth expected from the human pharmaceutical products.

Company Overview代写
Company Overview代写

Therapy areas  Company Overview代写

The pipeline growth opportunities for the company came from five therapy areas including oncology, pain, neurodegeneration, immunology, and diabetes. The company hoped to make the opportunities have positive financial outlook. Besides, the prospective investment opportunities will not only add value to the company’s revenue but also help in growth and diversification in the global market.

The above press release is essential in communication and informing the stakeholders particularly the investors of the general performance and prospects of the company. The release seeks to give hope of investment growth for its shareholders. It also clarifies the issues about running on the affairs and strategic plans of the company.

The financial report was forward-looking and hence reported a going concern company. According to the profits for the year 2018, the company has future financial stability. The investment prospects are an indication the company will continue to maintain its global competitiveness in the pharmaceutical industry.

References  Company Overview代写

Lilly Home. (n.d). About us. Retrieved from

Eli Lilly and Company. (2018). Eli Lilly and Company 2018 financial report, a notice of 2019 annual meeting and proxy statement (pp. 1-186). Indianapolis. Retrieved from

Lilly Media. (2018). Lilly announces financial guidance, reviews commercial performance, and highlights promising pipeline opportunities at an investment community meeting. Retrieved from

Company Overview代写
Company Overview代写


更多其他: Review代写 研究论文代写 文学论文代写 Report代写 Case study代写 Proposal代写 Capstone Projects  Essay代写 数据分析代写 Academic代写 商科论文代写 论文代写

合作平台:天才代写 幽灵代写  写手招聘